肝硬変(Liver Cirrhosis):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Liver Cirrhosis - Pipeline Review, H2 2014
◆商品コード:GMDHC5684IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:104
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における肝硬変(Liver Cirrhosis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・肝硬変(Liver Cirrhosis)の概要
・肝硬変(Liver Cirrhosis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・肝硬変(Liver Cirrhosis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・肝硬変(Liver Cirrhosis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・肝硬変(Liver Cirrhosis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Liver Cirrhosis – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Liver Cirrhosis – Pipeline Review, H2 2014’, provides an overview of the Liver Cirrhosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Liver Cirrhosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Liver Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Liver Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver Cirrhosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Liver Cirrhosis Overview 9
Therapeutics Development 10
Pipeline Products for Liver Cirrhosis – Overview 10
Pipeline Products for Liver Cirrhosis – Comparative Analysis 11
Liver Cirrhosis – Therapeutics under Development by Companies 12
Liver Cirrhosis – Therapeutics under Investigation by Universities/Institutes 14
Liver Cirrhosis – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Liver Cirrhosis – Products under Development by Companies 19
Liver Cirrhosis – Products under Investigation by Universities/Institutes 20
Liver Cirrhosis – Companies Involved in Therapeutics Development 21
ACROVIS biostructures GmbH 21
Alfa Wassermann S.p.A 22
Cellular Biomedicine Group, Inc. 23
Conatus Pharmaceuticals Inc. 24
Digna Biotech, S.L. 25
Galectin Therapeutics, Inc. 26
Gilead Sciences, Inc. 27
GNI Group Ltd. 28
Nitto Denko Corporation 29
Pacific Therapeutics Ltd. 30
PharmaIN Corporation 31
Pharmicell Co., Ltd. 32
Phenex Pharmaceuticals AG 33
S-Evans Biosciences, Inc. 34
Stelic Institute & Co. 35
Stempeutics Research Private Limited 36
Tobira Therapeutics, Inc. 37
Liver Cirrhosis – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
(sofosbuvir + GS-5816) – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cell Therapy for Liver Cirrhosis – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
cenicriviroc – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
DB-027 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DB-036 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
emricasan – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
F-351 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
GR-MD-01 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Livercellgram – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Monoclonal Antibodies to Antagonize Transforming Growth Factor Beta 1 for HCV associated Liver Cirrhosis – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ND-L02s0201 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PTL-303 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Px-104 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ReJoin – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
rifaximin – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules for Liver Diseases – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecules to Inhibit EGFR for Gastrointestinal Disorders – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Stem Cell Therapy for Liver Cirrhosis – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Stem Cell Therapy for Liver Cirrhosis – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Stem Cell Therapy for Liver Cirrhosis – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Stem Cell Therapy for Liver Cirrhosis – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Stempeucel – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
STNM-04 – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Thrombopoietin – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Undisclosed Peptide For Liver Cirrhosis – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Liver Cirrhosis – Recent Pipeline Updates 86
Liver Cirrhosis – Dormant Projects 96
Liver Cirrhosis – Discontinued Products 97
Liver Cirrhosis – Product Development Milestones 98
Featured News & Press Releases 98
Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting 98
Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting 99
Oct 06, 2014: New Anti-fibrosis Drug with Molecular Targeting DDS Starts Phase-1b Dosing for Cirrhosis Patients 100
Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension 100
Jan 20, 2011: Stempeutics Research’s Stempeucel LC Recieves DCGI Clearance To Start Phase II Clinical Trial For Liver Cirrhosis 101
Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI’s Key Therapeutic Product for Liver Disease 102
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

[List of Tables]
Number of Products under Development for Liver Cirrhosis, H2 2014 10
Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Liver Cirrhosis - Pipeline by ACROVIS biostructures GmbH, H2 2014 21
Liver Cirrhosis - Pipeline by Alfa Wassermann S.p.A, H2 2014 22
Liver Cirrhosis - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 23
Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc., H2 2014 24
Liver Cirrhosis - Pipeline by Digna Biotech, S.L., H2 2014 25
Liver Cirrhosis - Pipeline by Galectin Therapeutics, Inc., H2 2014 26
Liver Cirrhosis - Pipeline by Gilead Sciences, Inc., H2 2014 27
Liver Cirrhosis - Pipeline by GNI Group Ltd., H2 2014 28
Liver Cirrhosis - Pipeline by Nitto Denko Corporation, H2 2014 29
Liver Cirrhosis - Pipeline by Pacific Therapeutics Ltd., H2 2014 30
Liver Cirrhosis - Pipeline by PharmaIN Corporation, H2 2014 31
Liver Cirrhosis - Pipeline by Pharmicell Co., Ltd., H2 2014 32
Liver Cirrhosis - Pipeline by Phenex Pharmaceuticals AG, H2 2014 33
Liver Cirrhosis - Pipeline by S-Evans Biosciences, Inc., H2 2014 34
Liver Cirrhosis - Pipeline by Stelic Institute & Co., H2 2014 35
Liver Cirrhosis - Pipeline by Stempeutics Research Private Limited, H2 2014 36
Liver Cirrhosis - Pipeline by Tobira Therapeutics, Inc., H2 2014 37
Assessment by Monotherapy Products, H2 2014 38
Assessment by Combination Products, H2 2014 39
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 43
Number of Products by Stage and Route of Administration, H2 2014 45
Number of Products by Stage and Molecule Type, H2 2014 47
Liver Cirrhosis Therapeutics - Recent Pipeline Updates, H2 2014 86
Liver Cirrhosis - Dormant Projects, H2 2014 96
Liver Cirrhosis - Discontinued Products, H2 2014 97

[List of Figures]
Number of Products under Development for Liver Cirrhosis, H2 2014 10
Number of Products under Development for Liver Cirrhosis - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Products, H2 2014 17
Assessment by Monotherapy Products, H2 2014 38
Number of Products by Top 10 Targets, H2 2014 40
Number of Products by Stage and Top 10 Targets, H2 2014 40
Number of Products by Top 10 Mechanism of Actions, H2 2014 42
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 42
Number of Products by Top 10 Routes of Administration, H2 2014 44
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 45
Number of Products by Top 10 Molecule Types, H2 2014 46
Number of Products by Stage and Top 10 Molecule Types, H2 2014 47

【掲載企業】

ACROVIS biostructures GmbH
Alfa Wassermann S.p.A
Cellular Biomedicine Group, Inc.
Conatus Pharmaceuticals Inc.
Digna Biotech, S.L.
Galectin Therapeutics, Inc.
Gilead Sciences, Inc.
GNI Group Ltd.
Nitto Denko Corporation
Pacific Therapeutics Ltd.
PharmaIN Corporation
Pharmicell Co., Ltd.
Phenex Pharmaceuticals AG
S-Evans Biosciences, Inc.
Stelic Institute & Co.
Stempeutics Research Private Limited
Tobira Therapeutics, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[肝硬変(Liver Cirrhosis):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆